TLDR
- ArgusEye secures €2.8 million funding led by Voima Ventures and co-led by Eir Ventures
- The investment will support the development of the Auga™ sensor system platform to accelerate bioprocessing
ArgusEye, a provider of sensor solutions for real-time monitoring of biological systems, has closed a €2.8 million funding round led by Voima Ventures and co-led by Eir Ventures. This brings the total raised by the company to €3.45 million. The funding will be used to advance the development of the company’s sensor system platform, Auga™, designed to accelerate biotherapeutic development and manufacturing.
The company, founded in 2017 by Erik Martinsson and Daniel Aili, specializes in developing sensors for real-time monitoring and analysis of biological systems and processes. The AugaOne™ product, launched in March 2024, is the first product in the Auga platform and is tailored for downstream processing to enhance process efficiency and intensify process development for faster detection and quantification of mAbs.
The investment will enable ArgusEye to expand the Auga platform to support upstream bioprocessing and formulation of various target molecules, aiming to revolutionize biotherapeutic development and production. The company’s strategic focus is on geographical expansion and diversification of product offerings to cover the entire pharmaceutical process chain, from upstream cell growth to downstream purification and GMP production.
ArgusEye aims to deliver cutting-edge solutions to address industry demands, with a vision of making biomedicines more accessible and sustainable. With this funding and support from investors, the company is set to embark on its scale-up phase and continue its journey towards transforming biopharma manufacturing through real-time inline quality control.
